Tag Archives: Kevin McKernan

Courtagen-Life-sciences

Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent in the U.S.

Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent in the U.S.

WOBURN, Mass., Feb. 23, 2017 /Weed Wire/ — Courtagen Life Sciences, Inc., an innovative endocannabinoid platform and molecular information company, announced today that the company has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application no. 14/895,557, titled “Methods and Kits for Treating and Classifying Individuals at Risk of or Suffering from TRAP1 Change-of-Function.”

CannMed 2017

CannMed 2017 Conference Announces Expanded Speaker List for Medical Cannabis Health and Research Conference to be Held in Boston in April

WOBURN, Mass., Feb. 10, 2017 /Weed Wire/ — Medicinal Genomics and Courtagen Life Sciences, today announced an increasingly influential speaker lineup for CannMed 2017.

US researchers call for re-evaluation of microbial testing of Cannabis

US Researchers Call for Re-evaluation of Microbial Testing of Cannabis

A new US study suggests that some of the medicinal benefits of dispensary grade Cannabis could be compromised because the flowers host potentially harmful yeasts and toxic molds, which cannot be detected by industry standard culturing techniques.


Top